Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.